α1-Adrenergic Receptors Activate AKT via a Pyk2/PDK-1 Pathway That Is Tonically Inhibited by Novel Protein Kinase C Isoforms in Cardiomyocytes

• Published in: Circulation research 2006-12, Vol.99 (12), p.1367-1375
• Main Authors: Guo, Jianfen, Sabri, Abdelkarim, Elouardighi, Hasnae, Rybin, Vitalyi, Steinberg, Susan F
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Fundamental and applied biological sciences. Psychology; Vertebrates: cardiovascular system
• ISSN: 0009-7330; 1524-4571
• DOI: 10.1161/01.RES.0000252830.01581.fd

AKT is a potent antiapoptotic kinase, but its role in the cardioprotective actions of α1-adrenergic receptors (ARs) remains uncertain, because α1-ARs typically induce little-to-no AKT activation in most cardiomyocyte models. This study identifies a prominent α1-AR–dependent AKT activation pathway that is under tonic inhibitory control by novel protein kinase Cs (nPKCs) in neonatal rat cardiomyocyte cultures. We also implicate Pyk2, Pyk2 complex formation with PDK-1 and paxillin, and increased PDK-1–Y373/376 phosphorylation as the mechanism that links α1-AR activation to increased AKT phosphorylation. nPKCs (which are prominent α1-AR effectors) interfere with this α1-AR–dependent AKT activation by blocking Pyk2/PDK-1/paxillin complex formation and PDK-1–Y373/376 phosphorylation. Additional studies used an adenoviral-mediated overexpression strategy to show that Pyk2 exerts dual controls on antiapoptotic PDK-1/AKT and proapoptotic c-Jun N-terminal kinase (JNK) pathways. Although the high nPKC activity of most cardiomyocyte models favors Pyk2 signaling to JNK (and cardiac apoptosis), the cardioprotective actions of Pyk2 through the PDK-1/AKT pathway are exposed when PKC or JNK activation is prevented. Collectively, these studies identify JNK and AKT as functionally distinct downstream components of the α1-AR/Pyk2 signaling pathway. We also implicate nPKCs as molecular switches that control the balance of signaling via proapoptotic JNK and antiapoptotic PDK-1/AKT pathways, exposing a novel mechanism for nPKC-dependent regulation of cardiac hypertrophy and failure.